期刊文献+

甲苯磺酸索拉非尼在大鼠肠吸收特性的研究 被引量:2

下载PDF
导出
摘要 目的:考察甲苯磺酸索拉非尼在十二指肠、空肠、回肠、结肠的吸收情况。方法:采用大鼠在体单向灌流法,研究甲苯磺酸索拉非尼在大鼠各肠段的吸收动力学性质及不同药物浓度、P-gp抑制剂维拉帕米对其吸收的影响。结果与结论:甲苯磺酸索拉非尼在肠道中的吸收按结肠、十二指肠、空肠、回肠的顺序依次下降;浓度为5mg.L-1时,其Ka和Peff显著高于其他两个浓度(P<0.05);P-gp抑制剂维拉帕米对甲苯磺酸索拉非尼的吸收无影响(P>0.05)。
出处 《亚太传统医药》 2011年第3期39-41,共3页 Asia-Pacific Traditional Medicine
  • 相关文献

参考文献4

二级参考文献41

  • 1聂淑芳,潘卫三,李伟,杜玍妮.长春西汀的大鼠在体肠吸收研究[J].中国医药工业杂志,2005,36(10):625-628. 被引量:21
  • 2聂淑芳,潘卫三,杨星钢,刘宏飞,刘志东.对大鼠在体肠单向灌流技术中重量法的评价[J].中国新药杂志,2005,14(10):1176-1179. 被引量:90
  • 3陈孝天.抗厌氧菌感染的新药──替硝唑片[J].上海口腔医学,1996,5(2):120-120. 被引量:1
  • 4朱玲玲,李娟,王广基.地西泮的大鼠在体肠吸收机理研究[J].中国药科大学学报,2006,37(6):507-511. 被引量:15
  • 5[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
  • 6[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
  • 7[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
  • 8[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
  • 9[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
  • 10[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144

共引文献77

同被引文献14

  • 1张典瑞,任天池,娄红祥,邢洁.HPLC测定冬凌草甲素固态类脂纳米粒在小鼠肝脏中的药物浓度[J].中国药学杂志,2005,40(8):622-624. 被引量:9
  • 2杨素芳.论引经药的应用[J].福建中医学院学报,2007,17(4):49-50. 被引量:2
  • 3黄自通.HPLC法测定索拉非尼含量及有关物质[J].黑龙江科技信息,2007(10S):148-148. 被引量:4
  • 4Liovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359:378-390.
  • 5Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular caicinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10:25-34.
  • 6Abou-alfa GK,Johnson P,Knox JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial[J].JAMA,2010,304:2154-2160.
  • 7Piquet AC,Saar B,Hlushchuk R,et al.Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma[J].Mol CancerTher,2011,10(6):1007-1017.
  • 8Pawlik TM,Reyes DK,Cosqrove D,et al.Phase Ⅱ trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma[J].J Clin Oncol,2011,29 (30):3960-3967.
  • 9Han G,Yang J,Shao G,et al.Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma:a subgroup interim analisis of the START trial[J].Future Oncol,2013,9(3):403-410.
  • 10Minami H,Kawada K,Ebi H,et al.Phase Ⅰ and pharmacokinetic study of sorafenib,an oral muhikinase inhibitor,in Japanese patients with advanced refractory solid tumors[J].Cancer Sci,2008,99:1492-1498.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部